The role of nanotechnology in the treatment of viral infections
暂无分享,去创建一个
Thavendran Govender | Hendrik G Kruger | Lavanya Singh | T. Govender | G. E. Maguire | H. G. Kruger | R. Parboosing | L. Singh | Raveen Parboosing | Glenn E M Maguire | H. Kruger
[1] Arti Vashist,et al. Electrochemical Biosensors for Early Stage Zika Diagnostics. , 2017, Trends in biotechnology.
[2] M. Gagliardi. Biomimetic and bioinspired nanoparticles for targeted drug delivery. , 2017, Therapeutic delivery.
[3] F. Kashanchi,et al. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection , 2017, Journal of Neuroimmune Pharmacology.
[4] L. Chonco,et al. Potential inhibition of HIV-1 encapsidation by oligoribonucleotide–dendrimer nanoparticle complexes , 2017, International journal of nanomedicine.
[5] Yu-Cheng Su,et al. Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. , 2016, Analytical chemistry.
[6] M. Nair,et al. Recent trends on hydrogel based drug delivery systems for infectious diseases. , 2016, Biomaterials science.
[7] T. Govender,et al. Intracellular localization of gold nanoparticles with targeted delivery in MT-4 lymphocytes , 2016 .
[8] M. Yuen,et al. New pharmacological approaches to a functional cure of hepatitis B , 2016, Clinical liver disease.
[9] K. S. Rajan,et al. Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. , 2016, Colloids and surfaces. B, Biointerfaces.
[10] H. Xia,et al. Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways. , 2016, ACS applied materials & interfaces.
[11] Ajeet Kaushik,et al. Advancements in nano-enabled therapeutics for neuroHIV management , 2016, International journal of nanomedicine.
[12] Seung‐Woo Cho,et al. Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[13] A. Kaushik,et al. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. , 2016, Advanced drug delivery reviews.
[14] Y. Liu,et al. Role of nanotechnology in HIV/AIDS vaccine development. , 2016, Advanced drug delivery reviews.
[15] C. Lubich,et al. The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know? , 2016, Pharmaceutical Research.
[16] Vikas Sharma,et al. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies. , 2016, Protein expression and purification.
[17] M. Nair,et al. Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers , 2016, Scientific Reports.
[18] Pu Li,et al. Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C , 2016, Scientific Reports.
[19] Bin Zhou,et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. , 2016, Vaccine.
[20] Xuesi Chen,et al. Production and clinical development of nanoparticles for gene delivery , 2016, Molecular therapy. Methods & clinical development.
[21] P. Horby,et al. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial , 2016, PLoS medicine.
[22] L. Gostin,et al. The Emerging Zika Pandemic: Enhancing Preparedness. , 2016, JAMA.
[23] J. M. Lanao,et al. Current applications of nanoparticles in infectious diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[24] S. Kent,et al. Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination , 2016, Expert review of vaccines.
[25] A. Gulland. Zika virus is a global public health emergency, declares WHO , 2016, BMJ : British Medical Journal.
[26] T. Govender,et al. Binding Free Energy Calculations of Nine FDA‐approved Protease Inhibitors Against HIV‐1 Subtype C I36T↑T Containing 100 Amino Acids Per Monomer , 2016, Chemical biology & drug design.
[27] R. Gómez,et al. Nanotechnology as a New Therapeutic Approach to Prevent the HIV-Infection of Treg Cells , 2016, PloS one.
[28] G. Borchard,et al. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice. , 2016, Molecular pharmaceutics.
[29] V. Zarytova,et al. Nanoparticle-Mediated Nonviral DNA Delivery for Effective Inhibition of Influenza a Viruses in Cells , 2016, IEEE Transactions on Nanotechnology.
[30] Catharina de Lange Davies,et al. Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles , 2016, Journal of Nanobiotechnology.
[31] Mahesh Attimarad,et al. Formulation and evaluation of nano based drug delivery system for the buccal delivery of acyclovir. , 2015, Colloids and surfaces. B, Biointerfaces.
[32] S. Manzoor,et al. Hepatitis B virus therapy: What's the future holding for us? , 2015, World journal of gastroenterology.
[33] Yonghou Jiang,et al. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission. , 2015, Molecular pharmaceutics.
[34] S. Adesina,et al. Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy. , 2015, Molecular pharmaceutics.
[35] A. Ghaemi,et al. Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells , 2015, Artificial cells, nanomedicine, and biotechnology.
[36] A. Chávez-Reyes,et al. Therapeutic silencing of HPV 16 E7 by systemic administration of siRNA-neutral DOPC nanoliposome in a murine cervical cancer model with obesity. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[37] Liju Yang,et al. Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles , 2015, PloS one.
[38] O. Abián,et al. Shell Cross-Linked Polymeric Micelles as Camptothecin Nanocarriers for Anti-HCV Therapy. , 2015, Macromolecular bioscience.
[39] R. Boukherroub,et al. Nanostructures for the Inhibition of Viral Infections , 2015, Molecules.
[40] Y. Chai,et al. An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer. , 2015, Biosensors & bioelectronics.
[41] A. Bolhassani,et al. MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7. , 2015, Vaccine.
[42] S. Nekhai,et al. Activation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein Phosphatase-1-Targeting Compound , 2015, Scientia pharmaceutica.
[43] M. D. Hussain,et al. Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[44] V. Lohmann,et al. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication , 2015, Hepatology.
[45] N. Snead,et al. Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates , 2015, Nature.
[46] V. Valcour,et al. CNS reservoirs for HIV: implications for eradication , 2015, Journal of virus eradication.
[47] Amit Jain,et al. Nanotechnology: A magic bullet for HIV AIDS treatment , 2015, Artificial cells, nanomedicine, and biotechnology.
[48] M. Nair,et al. Sustained-release nanoART formulation for the treatment of neuroAIDS , 2015, International journal of nanomedicine.
[49] Seung Jun Oh,et al. Integration of reverse transcriptase loop-mediated isothermal amplification with an immunochromatographic strip on a centrifugal microdevice for influenza A virus identification. , 2015, Lab on a chip.
[50] Q. Wang,et al. A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma. , 2014, Current pharmaceutical design.
[51] I. Chaiken,et al. Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation* , 2014, The Journal of Biological Chemistry.
[52] D. Hazuda,et al. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.
[53] Hansoo Park,et al. Nanotechnology for diagnosis and treatment of infectious diseases. , 2014, Journal of nanoscience and nanotechnology.
[54] Joo Yeon Park,et al. Nanotechnology and vaccine development , 2014 .
[55] Benjamin Michen,et al. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages , 2014, Beilstein journal of nanotechnology.
[56] M. Tafaghodi,et al. Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin , 2014, Iranian journal of basic medical sciences.
[57] Piotr Orlowski,et al. Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection , 2014, PloS one.
[58] Yanfei Tao,et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[59] K. Chatterjee,et al. Core/shell nanoparticles in biomedical applications. , 2014, Advances in colloid and interface science.
[60] S. Penadés,et al. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs , 2014, Beilstein journal of organic chemistry.
[61] M. Radomski,et al. Pegylation increases platelet biocompatibility of gold nanoparticles. , 2014, Journal of biomedical nanotechnology.
[62] T. Ebensen,et al. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung. , 2014, Vaccine.
[63] Ji-Ho Park,et al. Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages. , 2014, ACS nano.
[64] Maria João Gomes,et al. Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system , 2014, International journal of nanomedicine.
[65] E. Petricoin,et al. The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics , 2014, Pathogens and disease.
[66] X. Guan,et al. Inhibition effect of silver nanoparticles on herpes simplex virus 2. , 2014, Genetics and molecular research : GMR.
[67] Dik van de Meent,et al. Cellular uptake of nanoparticles as determined by particle properties, experimental conditions, and cell type , 2014, Environmental toxicology and chemistry.
[68] M. Leal,et al. HIV Infection Deregulates the Balance Between Regulatory T Cells and IL-2–Producing CD4 T Cells by Decreasing the Expression of the IL-2 Receptor in Treg , 2014, Journal of acquired immune deficiency syndromes.
[69] C. Sabliov,et al. Nanodelivery of bioactive components for food applications: types of delivery systems, properties, and their effect on ADME profiles and toxicity of nanoparticles. , 2014, Annual review of food science and technology.
[70] Harvinder S Gill,et al. Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. , 2014, Nanomedicine.
[71] L. Lee,et al. Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs , 2014, International journal of nanomedicine.
[72] K. Yamanishi,et al. Chitosan Nanoparticle Encapsulated Hemagglutinin-Split Influenza Virus Mucosal Vaccine , 2013, AAPS PharmSciTech.
[73] Mahendra Rai,et al. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: A review , 2013, Applied Microbiology and Biotechnology.
[74] J. Lisziewicz,et al. Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial , 2013, Journal of acquired immune deficiency syndromes.
[75] S. Choudhary,et al. Development and In Vitro-In Vivo Evaluation of Oral Drug Delivery System of Acyclovir Loaded PLGA nanoparticles. , 2013 .
[76] A. Ingle,et al. Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3 , 2013, International journal of nanomedicine.
[77] Andrew J Thorley,et al. New perspectives in nanomedicine. , 2013, Pharmacology & therapeutics.
[78] C. Jeynes,et al. Measuring and modelling cell-to-cell variation in uptake of gold nanoparticles. , 2013, The Analyst.
[79] J. Majoral,et al. Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview , 2013 .
[80] Sanjiv Sonkaria,et al. Targeting C-type lectin receptors with multivalent carbohydrate ligands. , 2013, Advanced drug delivery reviews.
[81] O. Abián,et al. Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus , 2013, PloS one.
[82] J. Whittle,et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.
[83] G. Renukaradhya,et al. PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs , 2013, Veterinary Microbiology.
[84] J. DeSimone,et al. Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[85] K. Woodrow,et al. Drug Synergy of Tenofovir and Nanoparticle-Based Antiretrovirals for HIV Prophylaxis , 2013, PloS one.
[86] M. Kheiri,et al. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization , 2013, Archives of pharmacal research.
[87] J. Reineke,et al. Quantitative detection of PLGA nanoparticle degradation in tissues following intravenous administration. , 2013, Molecular pharmaceutics.
[88] Anthony E. Gregory,et al. Vaccine delivery using nanoparticles , 2013, Front. Cell. Infect. Microbiol..
[89] Michael Riediker,et al. Therapeutic nanoparticles in clinics and under clinical evaluation. , 2013, Nanomedicine.
[90] P. Gide,et al. Enhancement of Transdermal Penetration and Bioavailability of Poorly Soluble Acyclovir Using Solid Lipid Nanoparticles Incorporated in Gel Cream , 2013, Indian journal of pharmaceutical sciences.
[91] Linda Pastero,et al. Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. , 2013, International journal of pharmaceutics.
[92] H. Ploegh,et al. Sialylneolacto-N-tetraose c (LSTc)-bearing Liposomal Decoys Capture Influenza A Virus* , 2013, The Journal of Biological Chemistry.
[93] R. Adelung,et al. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. , 2012, Antiviral research.
[94] K. Kaur,et al. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. , 2012, Vaccine.
[95] Kwangmeyung Kim,et al. Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection. , 2012, ACS nano.
[96] Pascal Richette,et al. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents , 2012, Expert opinion on drug delivery.
[97] W. Law,et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future , 2012, International journal of nanomedicine.
[98] S. Barik. New treatments for influenza , 2012, BMC Medicine.
[99] M. Hua,et al. Potential of magnetic nanoparticles for targeted drug delivery. , 2012, Nanotechnology, science and applications.
[100] Jill M. Steinbach,et al. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. , 2012, Journal of Controlled Release.
[101] R. Sarid,et al. Surface-modified protein nanospheres as potential antiviral agents. , 2012, Chemical communications.
[102] Nicolas Bertrand,et al. The journey of a drug-carrier in the body: an anatomo-physiological perspective. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[103] Soon Hye Yang,et al. Nanoparticle-based artificial RNA silencing machinery for antiviral therapy , 2012, Proceedings of the National Academy of Sciences.
[104] Xi Jiang,et al. Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. , 2012, Nanomedicine.
[105] Benjamin C. Tang,et al. Mucus-Penetrating Nanoparticles for Vaginal Drug Delivery Protect Against Herpes Simplex Virus , 2012, Science Translational Medicine.
[106] N. Kuntworbe,et al. Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management , 2012 .
[107] S. Paria,et al. Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. , 2012, Chemical reviews.
[108] Glenn E. M. Maguire,et al. Nanotechnology and the Treatment of HIV Infection , 2012, Viruses.
[109] Xingyu Jiang,et al. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. , 2012, Biomaterials.
[110] J. Hubbell,et al. Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages , 2012, International journal of nanomedicine.
[111] R. Tilley,et al. Synthesis and Stability of Highly Crystalline and Stable Iron/Iron Oxide Core/Shell Nanoparticles for Biomedical Applications , 2012 .
[112] Weipeng Cao,et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.
[113] R. Kaul,et al. Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded Safety , 2012, Journal of acquired immune deficiency syndromes.
[114] Young Jik Kwon,et al. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[115] John T Elliott,et al. Stable nanoparticle aggregates/agglomerates of different sizes and the effect of their size on hemolytic cytotoxicity , 2011, Nanotoxicology.
[116] E. R. de Celis,et al. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[117] V. Patravale,et al. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. , 2011, Journal of biomedical nanotechnology.
[118] J. Burnett,et al. Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.
[119] M. Peng,et al. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. , 2011, International journal of pharmaceutics.
[120] H. H. Lara,et al. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds , 2011, Journal of nanobiotechnology.
[121] Sanyog Jain,et al. Enhanced dermal delivery of acyclovir using solid lipid nanoparticles , 2011, Drug Delivery and Translational Research.
[122] Yang Liu,et al. In vivo delivery of RNAi with lipid-based nanoparticles. , 2011, Annual review of biomedical engineering.
[123] Warren C W Chan,et al. Effect of gold nanoparticle aggregation on cell uptake and toxicity. , 2011, ACS nano.
[124] A. Baas,et al. FDA-approved poly(ethylene glycol)–protein conjugate drugs , 2011 .
[125] B. Richardson,et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004) , 2011, AIDS.
[126] Rainer H Müller,et al. State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[127] P. Hammond,et al. Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery. , 2011, Nano letters.
[128] M. Marsden,et al. Activation of Latent HIV Using Drug-Loaded Nanoparticles , 2011, PloS one.
[129] Lev Dykman,et al. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. , 2011, Chemical Society reviews.
[130] M. Zamora,et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. , 2011, American journal of respiratory and critical care medicine.
[131] Joelle M. Brown,et al. A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days , 2011, PloS one.
[132] P. Eastman. Progress Being Made on Potential of Microbicides to Prevent Genital HPV Infection , 2010 .
[133] Si-Shen Feng,et al. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. , 2010, International journal of pharmaceutics.
[134] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[135] D. Chiappetta,et al. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. , 2010, Colloids and surfaces. B, Biointerfaces.
[136] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[137] L. Rohan,et al. Progress in antiretroviral drug delivery using nanotechnology , 2010, International journal of nanomedicine.
[138] Jianqing Gao,et al. Potential neurotoxicity of nanoparticles. , 2010, International journal of pharmaceutics.
[139] Xinying Wu,et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.
[140] E. Goldys,et al. Non-specific cellular uptake of surface-functionalized quantum dots , 2010, Nanotechnology.
[141] H. Sharma,et al. Conference scene: Nanoneuroprotection and nanoneurotoxicity: recent progress and future perspectives. , 2010, Nanomedicine.
[142] Joshua C. Johnson,et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.
[143] P. Couvreur,et al. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. , 2010, Bioorganic & medicinal chemistry letters.
[144] Rob Lambkin-Williams,et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.
[145] Chad A. Mirkin,et al. Gold nanoparticles for biology and medicine. , 2010, Angewandte Chemie.
[146] Rasesh Y Parikh,et al. Biological synthesis of metallic nanoparticles. , 2010, Nanomedicine : nanotechnology, biology, and medicine.
[147] N. K. Jain,et al. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. , 2010, Advanced drug delivery reviews.
[148] V. Mosqueira,et al. Nanotechnology applied to the treatment of malaria. , 2010, Advanced drug delivery reviews.
[149] R. Hurt,et al. Ion release kinetics and particle persistence in aqueous nano-silver colloids. , 2010, Environmental science & technology.
[150] R. Langer,et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.
[151] C. Rodríguez-Padilla,et al. Mode of antiviral action of silver nanoparticles against HIV-1 , 2010, Journal of nanobiotechnology.
[152] A. Moscona,et al. Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.
[153] J. Blackard,et al. Human Regulatory T Cells Are Targets for Human Immunodeficiency Virus (HIV) Infection, and Their Susceptibility Differs Depending on the HIV Type 1 Strain , 2009, Journal of Virology.
[154] P. Hamal,et al. Antifungal activity of silver nanoparticles against Candida spp. , 2009, Biomaterials.
[155] T. Shibamoto,et al. Effect of nanoparticles on the male reproductive system of mice. , 2009, International journal of andrology.
[156] Nelson A. Ochekpe,et al. Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery , 2009 .
[157] C. Herzog,et al. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. , 2009, Vaccine.
[158] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[159] Gabriele Neumann,et al. Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.
[160] Rajesh Singh,et al. Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.
[161] K. Fukuzaki,et al. Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer1 , 2009, The Journal of Immunology.
[162] J. Nauta,et al. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity. , 2009, Vaccine.
[163] A. Bourinbaiar,et al. Clinical experience with therapeutic vaccines designed for patients with hepatitis. , 2009, Current pharmaceutical design.
[164] M. Stevanović,et al. Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins , 2009 .
[165] Yvonne Perrie,et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.
[166] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. , 2008, Journal of pharmaceutical sciences.
[167] M. Jafelicci,et al. Iron Oxide Versus Fe $_{55}$ Pt $_{45}$ /Fe $_{3}$ O $_{4}$ : Improved Magnetic Properties of Core/Shell Nanoparticles for Biomedical Applications , 2008 .
[168] Qingxiu Wang,et al. Integrated metabolomic analysis of the nano-sized copper particle-induced hepatotoxicity and nephrotoxicity in rats: a rapid in vivo screening method for nanotoxicity. , 2008, Toxicology and applied pharmacology.
[169] P. Bovier. Epaxal®: a virosomal vaccine to prevent hepatitis A infection , 2008, Expert review of vaccines.
[170] Menachem Elimelech,et al. Aggregation kinetics of multiwalled carbon nanotubes in aquatic systems: measurements and environmental implications. , 2008, Environmental science & technology.
[171] Stephanie E. A. Gratton,et al. The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.
[172] Nuria Sanvicens,et al. Multifunctional nanoparticles--properties and prospects for their use in human medicine. , 2008, Trends in biotechnology.
[173] Samir Mitragotri,et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[174] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[175] John Crittenden,et al. Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light , 2008, Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering.
[176] W. D. de Jong,et al. Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.
[177] T. Nomura,et al. Regulatory T Cells and Immune Tolerance , 2008, Cell.
[178] Christian Melander,et al. Inhibition of HIV fusion with multivalent gold nanoparticles. , 2008, Journal of the American Chemical Society.
[179] L. Zhang,et al. Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.
[180] Robert Langer,et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.
[181] E. Poeschla,et al. Integrase, LEDGF/p75 and HIV replication , 2008, Cellular and Molecular Life Sciences.
[182] L. Stanberry,et al. VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection , 2007, International journal of nanomedicine.
[183] W. Chan,et al. Nanotoxicity: the growing need for in vivo study. , 2007, Current opinion in biotechnology.
[184] T. Tatusova,et al. The Influenza Virus Resource at the National Center for Biotechnology Information , 2007, Journal of Virology.
[185] Y. Kuo,et al. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. , 2007, International journal of pharmaceutics.
[186] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[187] Á. Delgado,et al. Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. , 2007, International journal of pharmaceutics.
[188] E. Shusta,et al. Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.
[189] Kemin Wang,et al. Preparation and antibacterial activity of Fe3O4@Ag nanoparticles , 2007 .
[190] Shibo Jiang,et al. Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide , 2007, Cell.
[191] Mansoor M. Amiji,et al. Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.
[192] K. Letchford,et al. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[193] Soo-Yon Rhee,et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.
[194] Michael S. Goldberg,et al. Nanostructured materials for applications in drug delivery and tissue engineering , 2007, Journal of biomaterials science. Polymer edition.
[195] N. K. Jain,et al. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro , 2007, Journal of drug targeting.
[196] Long Jiang,et al. Influence of Generation 2–5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/ TAR RNA Binding in HIV‐1 Transcription , 2006, Chemical biology & drug design.
[197] N Toub,et al. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. , 2006, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[198] A. Bandyopadhyay,et al. Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[199] Christopher J. Destache,et al. Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System , 2006, Journal of Neuroimmune Pharmacology.
[200] Wolfgang J Parak,et al. Laser-induced release of encapsulated materials inside living cells. , 2006, Angewandte Chemie.
[201] P. Couvreur,et al. Nanotechnology: Intelligent Design to Treat Complex Disease , 2006, Pharmaceutical Research.
[202] J. Doorbar,et al. Molecular biology of human papillomavirus infection and cervical cancer. , 2006, Clinical science.
[203] T. Xia,et al. Toxic Potential of Materials at the Nanolevel , 2006, Science.
[204] Malcolm L. H. Green,et al. Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.
[205] S. Cosgrove. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[206] Gregory Gregoriadis,et al. The ‘Co-Delivery’ Approach to Liposomal Vaccines: Application to the Development of influenza-A and hepatitis-B Vaccine Candidates , 2006, Journal of liposome research.
[207] Anne-Marie Caminade,et al. Characterization of dendrimers. , 2005, Advanced drug delivery reviews.
[208] Tetsuya Osaka,et al. THE STUDY OF ANTIMICROBIAL ACTIVITY AND PRESERVATIVE EFFECTS OF NANOSILVER INGREDIENT , 2005 .
[209] W. Couet,et al. Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice , 2005, Pharmaceutical Research.
[210] Claudia Fruijtier-Pölloth. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. , 2005, Toxicology.
[211] C. Che,et al. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. , 2005, Chemical communications.
[212] Michael S Saag,et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.
[213] M. Sjogren. Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. , 2005, The American journal of medicine.
[214] R. Bartenschlager,et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.
[215] Andre F Palmer,et al. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. , 2005, Biomacromolecules.
[216] R. Srinivasan,et al. Is polyethylene glycol safe and effective for chronic constipation in children? , 2005, Archives of Disease in Childhood.
[217] Andrea Scozzafava,et al. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. , 2005, Current pharmaceutical design.
[218] Thomas Rades,et al. Lipid based particulate formulations for the delivery of antigen , 2005, Immunology and cell biology.
[219] C. Murphy,et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. , 2005, Small.
[220] S. Akira,et al. Involvement of Toll-like Receptor 3 in the Immune Response of Lung Epithelial Cells to Double-stranded RNA and Influenza A Virus* , 2005, Journal of Biological Chemistry.
[221] Chad A. Mirkin,et al. Nanobiotechnology :concepts, applications and perspectives , 2005 .
[222] Steven F Dowdy,et al. Cationic TAT peptide transduction domain enters cells by macropinocytosis. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[223] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[224] A. Banerjee,et al. Role of Nucleolin in Human Parainfluenza Virus Type 3 Infection of Human Lung Epithelial Cells , 2004, Journal of Virology.
[225] Mark S. Sundrud,et al. HIV Infection of Naturally Occurring and Genetically Reprogrammed Human Regulatory T-cells , 2004, PLoS biology.
[226] Vincent M Rotello,et al. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. , 2004, Bioconjugate chemistry.
[227] Stuart T. Nichol,et al. Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome , 2004, Journal of Virology.
[228] G. Reinhardt,et al. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal®) in healthy toddlers and children in Chile , 2004, Acta paediatrica.
[229] R B Sim,et al. Proteases of the complement system. , 2004, Biochemical Society transactions.
[230] S. Sahoo,et al. Nanotech approaches to drug delivery and imaging. , 2003, Drug discovery today.
[231] Jayanth Panyam,et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[232] Raoul Kopelman,et al. Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications. , 2003, Journal of biomedical materials research. Part A.
[233] J. Baker,et al. Inactivation of Ebola virus with a surfactant nanoemulsion. , 2003, Acta tropica.
[234] H. Fessi,et al. Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis , 2003, Annals of tropical medicine and parasitology.
[235] E. Vivés,et al. TAT peptide internalization: seeking the mechanism of entry. , 2003, Current protein & peptide science.
[236] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[237] R. Mischler,et al. Inflexal V a trivalent virosome subunit influenza vaccine: production. , 2002, Vaccine.
[238] Alexander V Kabanov,et al. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[239] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[240] Bo Nilsson,et al. C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1 , 2002, The Journal of Immunology.
[241] B. Murphy,et al. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. , 2002, Virology.
[242] H. Klenk,et al. Functional balance between haemagglutinin and neuraminidase in influenza virus infections , 2002, Reviews in medical virology.
[243] M. Garnett,et al. Targeted drug conjugates: principles and progress. , 2001, Advanced drug delivery reviews.
[244] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[245] A. R. Kulkarni,et al. Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[246] M. Ghannoum,et al. New targets and delivery systems for antifungal therapy. , 2000, Medical mycology.
[247] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[248] R. Murray,et al. Monolayer-protected cluster molecules. , 2000, Accounts of chemical research.
[249] D. Cooper,et al. HIV protease inhibitors , 1996, AIDS.
[250] R. G. Freeman,et al. Preparation and Characterization of Au Colloid Monolayers , 1995 .
[251] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[252] L. Corey,et al. Treatment of herpes simplex virus infections. , 1987, Clinics in laboratory medicine.
[253] R. Reichman. Herpes simplex virus infections , 1984, European Journal of Clinical Microbiology.
[254] O. Laskin. Clinical Pharmacokinetics of Acyclovir , 1983, Clinical pharmacokinetics.
[255] byBrooke LaBranche,et al. Gold nanoparticles in delivery applications ? , 2018 .
[256] Tejabhiram Yadavalli,et al. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[257] M. Swartz,et al. A Polypropylene sulfide nanoparticle p24 vaccine promotes dendritic cell-mediated specific immune responses against HIV-1 , 2016 .
[258] D. M.,et al. Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. , 2016, The New England journal of medicine.
[259] M. López-Quintela,et al. Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects , 2015 .
[260] Chun-Xia Zhao,et al. Nanoparticle vaccines. , 2014, Vaccine.
[261] V. Labhasetwar,et al. Nanoparticles: cellular uptake and cytotoxicity. , 2014, Advances in experimental medicine and biology.
[262] M. Joshi,et al. Nanomedicines for treatment of viral diseases. , 2013, Critical reviews in therapeutic drug carrier systems.
[263] R. Cavalli,et al. Enhanced antiviral activity of acyclovir loaded into nanoparticles. , 2012, Methods in enzymology.
[264] S. Mohapatra,et al. Nanotechnology Applications to HIV Vaccines and Microbicides , 2012, Journal of global infectious diseases.
[265] Scott E McNeil,et al. Unique benefits of nanotechnology to drug delivery and diagnostics. , 2011, Methods in molecular biology.
[266] A. Denys. [Antiviral drugs]. , 2011, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.
[267] R. Bawa. Nanopharmaceuticals: Nanopharmaceuticals , 2010 .
[268] Marie-Pierre de Béthune,et al. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.
[269] T. Cihlar,et al. Current status and challenges of antiretroviral research and therapy. , 2010, Antiviral research.
[270] T. Cihlar,et al. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.
[271] Wen-chao Song,et al. Complement and its role in innate and adaptive immune responses , 2010, Cell Research.
[272] Frederick Hayden,et al. Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[273] Samir Mitragotri,et al. Physical approaches to biomaterial design. , 2009, Nature materials.
[274] M. Rai,et al. Silver nanoparticles as a new generation of antimicrobials. , 2009, Biotechnology advances.
[275] M. S. Muthu,et al. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. , 2009, Nanomedicine.
[276] H. Fessi,et al. olymer-based nanocapsules for drug delivery , 2009 .
[277] Krishnakiran Medepalli,et al. Advanced nanomaterials for biomedical applications , 2008 .
[278] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[279] Samir Mitragotri,et al. Shape Induced Inhibition of Phagocytosis of Polymer Particles , 2008, Pharmaceutical Research.
[280] Hari Singh Nalwa,et al. Handbook of nanostructured materials and nanotechnology , 2000 .
[281] Dorothea Pfeiffer,et al. Biosensoren: Grundlagen und Anwendungen , 1995 .
[282] Mathias Brust,et al. Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system , 1994 .
[283] E. Åkerblom,et al. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. , 1984, International archives of allergy and applied immunology.
[284] G. Frens. Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions , 1973 .
[285] J W DUGGAN,et al. Herpes simplex virus. , 1961, Transactions of the Canadian Ophthalmological Society.
[286] J. Hillier,et al. A study of the nucleation and growth processes in the synthesis of colloidal gold , 1951 .